STOCK TITAN

Can-Fite Biopharma Ltd - CANF STOCK NEWS

Welcome to our dedicated news page for Can-Fite Biopharma (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Can-Fite Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Can-Fite Biopharma's position in the market.

Rhea-AI Summary
XYZ Pharmaceuticals (XYZ) Announces Clinical Trial to Enroll Patients for New Drug Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a patient in their Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson. The company reported financial results, clinical milestones, and drug development advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a definitive agreement for the exercise of outstanding warrants to purchase up to 1,963,637 American Depositary Shares (ADSs) at a reduced exercise price of $1.53 per share. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announces a patient treated with namodenoson in the Phase II Liver Cancer Study has achieved a complete response and 6.9 years overall survival. The FDA and EMA have approved a pivotal Phase III clinical study, enrolling patients in Israel, Europe, and the US. Namodenoson has Orphan Drug and Fast Track Status for the treatment of HCC. The market for HCC treatments is estimated to reach $3.8 billion by 2027 for the G8 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
none
-
Rhea-AI Summary
Can-Fite BioPharma announced that the scientific journal Biomolecules published an article on the drug candidate namodenoson, highlighting its inhibition of pancreatic carcinoma growth and its mechanism of action. The company is developing an exploratory Phase II study to evaluate the safety and efficacy of namodenoson in treating patients with pancreatic carcinoma who failed first-line therapy. Namodenoson is also being evaluated in a Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
Rhea-AI Summary
Can-Fite BioPharma has entered into an agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI and ML techniques. The project aims to develop next-generation A3 adenosine receptor drug agonists that reduce development time and cost. Can-Fite will perform testing and validation of the drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary
Can-Fite BioPharma announces participation in BioJapan Conference for one-on-one meetings with Japanese companies specializing in Orphan Drugs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.48%
Tags
none
-
Rhea-AI Summary
Can-Fite BioPharma announces positive pre-clinical results for Namodenoson in inhibiting pancreatic carcinoma growth. Namodenoson showed significant growth inhibition and de-regulation of the Wnt and KRAS pathways responsible for the disease. Exploratory Phase II protocol for pancreatic carcinoma patients to be submitted for approval in Israel and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none
Rhea-AI Summary
Can-Fite BioPharma CEO to present at H.C. Wainwright Conference, highlighting advanced stage pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Can-Fite Biopharma Ltd

NYSE:CANF

CANF Rankings

CANF Stock Data

10.48M
1.50B
4.89%
0.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O Box 7537

About CANF

can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.